Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 12, 2023, by Ultragenyx Pharmaceutical Inc., a biotechnology company incorporated in Delaware. The filing primarily addresses Item 5.02 regarding the appointment of a new executive officer and Item 7.01 regarding Regulation FD disclosure.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes and Executive Appointment
On July 12, 2023, the Company announced the appointment of Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy, effective October 16, 2023. Mr. Horn previously served as CFO at Vir Biotechnology, Inc. and held senior finance roles at Biogen and McKinsey & Company.
Compensation and Severance Arrangements
- Base Salary: $590,000 per year.
- Annual Bonus: Target of 50% of base salary, effective 2024, subject to performance goals.
- Sign-on Bonus: One-time payment of $60,000.
- Equity Award: Target value of $6.0 million, split 50% stock options and 50% restricted stock units (RSUs), subject to Compensation Committee approval. Vesting occurs over four years.
- Severance (Without Cause/Constructive Termination): 12 months of base salary plus target bonus, 12 months of COBRA reimbursement, and extended option exercise period.
- Severance (Change in Control): If termination occurs within 18 months of a Covered Transaction, benefits include accelerated equity vesting, 18 months of base salary plus 1.5x target bonus, and 18 months of COBRA reimbursement.
Outlook, Risks, and Contingencies
The filing does not contain updated financial guidance, risk factors, or contingencies beyond the standard terms of the executive employment agreement. The Company noted that the Offer Letter is incorporated by reference as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the final approval of the $6.0 million equity award by the Compensation Committee.
- Confirm the exact grant date to determine the exercise price for options and the number of RSUs issued.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "Cause" and "Constructive Termination."
- Monitor the Company's cash position to assess the impact of the new executive compensation package on future liquidity.